Top

Published in:

01-05-2015 | Original Article

Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2

Authors: Yoshiteru Maeda, Atsushi Suzuki, Junnichi Ishii, Sahoko Sekiguchi-Ueda, Megumi Shibata, Yasumasa Yoshino, Shogo Asano, Nobuki Hayakawa, Kazuhiro Nakamura, Yasukazu Akiyama, Fumihiko Kitagawa, Toshiaki Sakuishi, Takashi Fujita, Shuji Hashimoto, Yukio Ozaki, Mitsuyasu Itoh

Published in: Heart and Vessels | Issue 3/2015

Abstract

Urinary liver-type fatty acid-binding protein (L-FABP) reflects the degree of stress in proximal tubules of the kidney. We examined the level of L-FABP in type-2 diabetes mellitus (T2DM) patients with chronic kidney disease (CKD) stage G1 and G2, and its relationship with cardiac markers and electrocardiographic (ECG) abnormalities. T2DM patients whose estimated glomerular filtration rate (eGFR) was ≥60 mL/min/1.73 m² were recruited [n = 276 (165 males), mean age 64 years]. The median level of urinary L-FABP was 6.6 μg/gCr. Urinary L-FABP showed significant correlation with urinary albumin-to-creatinine ratio (ACR) (r = 0.51, p < 0.0001). Median (25th–75th percentile) eGFR was 82 (72–95) mL/min/1.73 m². We divided patients into four subgroups (group 1, L-FABP ≤8.4 μg/gCr and ACR ≤30 mg/gCr; group 2, L-FABP ≤8.4 μg/gCr and ACR >30 mg/gCr; group 3, L-FABP >8.4 μg/gCr and ACR ≤30 mg/gCr; group 4, L-FABP >8.4 μg/gCr and ACR >30 mg/gCr). Compared with group 1, group 4 was significantly higher in systolic blood pressure, and eGFR using standardized serum cystatin C, high-sensitivity troponin T, and N-terminal pro-brain natriuretic peptide (NT-proBNP). Group 4 had significantly higher level of NT-proBNP than group 3. Groups 2, 3 and 4 showed more ECG abnormalities than group 1. These findings suggest that simultaneous measurement of urinary L-FABP and ACR should be useful to assess cardiovascular damage reflecting on the elevation of cardiac markers and ECG abnormalities in T2DM with CKD G1 and G2.

Meguid El Nahas A, Bello AK (2005) Chronic kidney disease: the global challenge. Lancet 365:331–340CrossRefPubMed

Barsoum RS (2006) Chronic kidney disease in the developing world. N Engl J Med 354:997–999CrossRefPubMed

Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG, Chronic Kidney Disease Prognosis Consortium (2012) Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 380:1662–1673CrossRefPubMedCentralPubMed

Kalansooriya A, Jennings P, Haddad F, Holbrook I, Whiting PH (2007) Urinary enzyme measurements as early indicators of renal insult in type 2 diabetes. Br J Biomed Sci 64:153–156PubMed

Unsal A, Koc Y, Basturk T, Akgun AO, Sakaci T, Ahbap E (2012) Risk factors for progression of renal disease in patient with diabetic nephropathy. Eur Rev Med Pharmacol Sci 16:878–883PubMed

Cohen-Bucay A, Viswanathan G (2012) Urinary markers of glomerular injury in diabetic nephropathy. Int J Nephro : 146987. doi: 10.1155/2012/146987

Saito T, Mochizuki T, Uchida K, Tsuchiya K, Nitta K (2013) Metabolic syndrome and risk of progression of chronic kidney disease: a single-center cohort study in Japan. Heart Vessels 28:323–329CrossRefPubMed

Tang SC, Lai KN (2012) The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol Dial Transplant 27:3049–3056CrossRefPubMed

Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed

10.

Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169CrossRefPubMed

11.

Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, Sagara K, Otsuka T, Matsuno S, Kano H, Uejima T, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T (2013) Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention. Heart Vessels. doi:10.1007/s00380-013-0382-6

12.

Araki S, Haneda M, Koya D, Kashiwagi A, Uzu T, Kikkawa R (2008) Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 82(Suppl 1):S54–S58CrossRefPubMed

13.

Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081CrossRef

14.

Veerkamp JH, Peeters RA, Maatman RG (1991) Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1081:1–24CrossRefPubMed

15.

Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M (2004) Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 143:23–30CrossRefPubMed

16.

Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K (2005) Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 145:125–133CrossRefPubMed

17.

Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K (2006) Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 284:175–182CrossRefPubMed

18.

Kamijo-Ikemori A, Sugaya T, Kimura K (2006) Urinary fatty acid binding protein in renal disease. Clin Chim Acta 374:1–7CrossRefPubMed

19.

Katoh H, Nozue T, Kimura Y, Nakata S, Iwaki T, Kawano M, Kawashiri MA, Michishita I, Yamagishi M (2013) Elevation of urinary liver-type fatty acid-binding protein as predicting factor for occurrence of contrast-induced acute kidney injury and its reduction by hemodiafiltration with blood suction from right atrium. Heart Vessels. doi:10.1007/s00380-013-0347-9

20.

von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM (2010) Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest 40:95–102CrossRef

21.

Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, Kaise R, Ishimitsu T, Tanaka Y, Kimura K (2011) Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 34:691–696CrossRefPubMedCentralPubMed

22.

Fukuda Y, Miura S, Zhang B, Iwata A, Kawamura A, Nishikawa H, Shirai K, Saku K (2009) Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease. Intern Med 48:1731–1737CrossRefPubMed

23.

Matsumori R, Shimada K, Kiyanagi T, Hiki M, Fukao K, Hirose K, Ohsaka H, Miyazaki T, Kume A, Yamada A, Takagi A, Ohmura H, Miyauchi K, Daida H (2012) Clinical significance of the measurements of urinary liver-type fatty acid binding protein levels in patients with acute coronary syndrome. J Cardiol 60:168–173CrossRefPubMed

24.

Araki S, Haneda M, Koya D, Sugaya T, Isshiki K, Kume S, Kashiwagi A, Uzu T, Maegawa H (2013) Predictive effects of urinary liver-type Fatty Acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 36:1248–1253CrossRefPubMedCentralPubMed

25.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in japan. Am J kidney Dis 53:982–992CrossRefPubMed

26.

Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S, Collaborators Developing the Japanese Equation for Estimated GFR (2013) GFR estimation using standardized serum cystatin C in Japan. Am J kidney Dis 61:197–203CrossRefPubMed

27.

Atsunori K, Masato K, Eiichi A, Yoshitomo O, Toshiaki H, Kume S, Kashiwagi A, Uzu T, Maegawa H (2012) International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 3:39–40CrossRef

28.

Taub PR, Borden KC, Fard A, Maisel A (2012) Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome. Expert Rev Cardiovasc Ther 10:657–667CrossRefPubMedCentralPubMed

29.

Hildebrandt P, Richards AM (2008) Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol 2101:21–24CrossRef

30.

Hildebrandt P (2009) Natriuretic peptides: prediction of cardiovascular disease in the general population and high risk populations. Dis Markers 26:227–233CrossRefPubMedCentralPubMed

31.

Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS (2002) Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 40:2065–2071CrossRefPubMed

32.

Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, Ando T, Kurokawa H, Kondo T, Nagamura Y, Ezaki K, Hishida H (2002) Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 89:691–695CrossRefPubMed

33.

Ishii J, Cui W, Kitagawa F, Kuno T, Nakamura Y, Naruse H, Mori Y, Ishikawa T, Nagamura Y, Kondo T, Oshima H, Nomura M, Ezaki K, Hishida H (2003) Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 49:2020–2026CrossRefPubMed

34.

Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction (2007) Universal definition of myocardial infarction. J Am Coll Cardiol 50:2173–2195CrossRefPubMed

35.

Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, Lindahl B, Giannitsis E, Hasin Y, Galvani M, Tubaro M, Alpert JS, Biasucci LM, Koenig W, Mueller C, Huber K, Hamm C, Jaffe AS, Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care (2010) Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 31:2197–2204CrossRefPubMed

36.

Asano S, Suzuki A, Ishii J, Sekiguchi-Ueda S, Shibata M, Yoshino Y, Nakamura K, Akiyama Y, Kitagawa F, Sakuishi T, Fujita T, Itoh M (2012) Use of a new assay for high-sensitivity cardiac troponin t for stratifying the risk of cardiovascular disease in outpatients with type-2 diabetes. Diabetology Int 3:29–36CrossRef

37.

Smathers RL, Galligan JJ, Shearn CT, Fritz KS, Mercer K, Ronis M, Orlicky DJ, Davidson NO, Petersen DR (2013) Susceptibility of L-FABP-/- mice to oxidative stress in early-stage alcoholic liver. J Lipid Res 54:1335–1345CrossRefPubMedCentralPubMed

38.

Atshaves BP, Martin GG, Hostetler HA, McIntosh AL, Kier AB, Schroeder F (2010) Liver fatty acid-binding protein and obesity. J Nutr Biochem 21:1015–1032CrossRefPubMedCentralPubMed

Title: Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2
Authors: Yoshiteru Maeda
Atsushi Suzuki
Junnichi Ishii
Sahoko Sekiguchi-Ueda
Megumi Shibata
Yasumasa Yoshino
Shogo Asano
Nobuki Hayakawa
Kazuhiro Nakamura
Yasukazu Akiyama
Fumihiko Kitagawa
Toshiaki Sakuishi
Takashi Fujita
Shuji Hashimoto
Yukio Ozaki
Mitsuyasu Itoh
Publication date: 01-05-2015
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 3/2015
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-014-0489-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Impact of sleep-disordered breathing on myocardial damage and metabolism in patients with chronic heart failure

Prognostic impact of regional arterial stiffness in hypertensive patients

A prognostic index for risk stratification for acute heart failure and death in subjects with ischemic cardiomyopathy and cardiac defibrillator

Coronary atherosclerotic lesions in patients with a ruptured abdominal aortic aneurysm

ECMO for pulmonary rescue in an adult with amiodarone-induced toxicity

The protective effect of heat shock protein 70 (Hsp70) in atrial fibrillation in various cardiomyopathy conditions